InterVenn Biosciences, a precision diagnostics company advancing liquid biopsy with glycoproteomics, and Aranscia, a global provider of award-winning clinical workflow and diagnostic technology ...

To improve ovarian cancer screening, researchers led by Johns Hopkins University’s Victor E. Velculescu, MD, PhD, developed a combination liquid biopsy approach. It has three components: measurements ...

A novel artificial intelligence (AI) protocol called DeepHRD was able to predict homologous recombination deficiency (HRD) in ovarian and breast cancers directly from routine histopathological slides.

First women’s health test marks a new chapter for InterVenn, providing access to non-invasive testing that differentiates between cancerous and benign pelvic masses for improved treatment planning ...

Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. So one of the biggest challenges in ovarian ...

Early-stage gynecologic cancer is confined to its original site and often treatable; diagnosis, surgery, and new therapies improve outcomes. Your diagnosis of an early-stage (Stage 1) gynecologic ...

Liquid biopsies analyze materials like circulating tumor DNA (ctDNA) in the blood to provide a non-invasive look at a cancer’s genetic profile. They are highly effective for tracking tumor evolution, ...

To date, the "liquid biopsy," a blood test that detects evidence of cancer in the circulation, has generated a lot of excitement in the lab but little in the clinic. The only liquid biopsy currently ...